NBIX – neurocrine biosciences, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NBIX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/22

10:23 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/10

11:34 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/10

11:34 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/7

02:12 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/7

02:12 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/7

10:22 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/7

08:42 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/7

08:42 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/6

12:54 pm

nbix

Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.

Low Report

Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.

Report

4/6

12:20 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

4/6

12:20 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

3/12

02:05 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

2/25

06:24 am

nbix

Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".

Low Report

Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".

Report

2/25

06:24 am

nbix

Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".

Low Report

Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".

Report

2/24

08:00 am

nbix

Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.

Low Report

Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.

Report

2/24

08:00 am

nbix

Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.

Low Report

Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.

Report

2/24

07:13 am

nbix

Rating for NBIX

Medium Report

Rating for NBIX

Report

2/24

07:13 am

nbix

Rating for NBIX

Medium Report

Rating for NBIX

Report

2/23

04:16 pm

nbix

Neurocrine initiated with an Outperform at Wolfe Research

Low Report

Neurocrine initiated with an Outperform at Wolfe Research

Report

2/23

04:16 pm

nbix

Neurocrine initiated with an Outperform at Wolfe Research

Low Report

Neurocrine initiated with an Outperform at Wolfe Research

Report

2/17

02:30 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

2/13

09:39 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

2/13

09:39 am

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

2/12

02:30 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

2/12

02:30 pm

nbix

Rating for NBIX

Low Report

Rating for NBIX

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.